Close menu




July 24th, 2020 | 07:30 CEST

NEL ASA, Royal Helium, SolGold - profit lies in purchasing

  • Investments
Photo credits: pixabay.com

These are exciting times for investors who focus on trends and technologies. Mobility is a hotly debated topic of the present. The storage of energy plays a decisive role alongside its generation. Those who can demonstrate solutions in this market have a lucrative future ahead of them. There are also niches that offer great added value and are indispensable for a modern society. In addition, the topic of asset protection is of concern to people around the globe. More than ever before, it is worth thinking about strategic investments.

time to read: 2 minutes | Author: Mario Hose
ISIN: NO0010081235 , CA78029U2056 , GB00B0WD0R35

Table of contents:


    Potential in the inert gas business

    Elon Musk has big plans in space and will need a lot of helium in the future. The inert gas cannot be produced artificially and must therefore be extracted from appropriate deposits or extracted from natural gas. In space travel, helium is used to control rockets. The largest market for helium, however, is the health sector, as magnetic resonance imaging (MRI) requires around 20% of the available noble gas every year. About 14% of the supply is used for welding. However, the largest single customer is Nasa, which works closely with Musk's SpaceX.

    To ensure that sufficient helium will continue to be available for modern society, Royal Helium has secured about 400,000 hectares of properties for the exploration and production of the noble gas in North America. With this portfolio, the company is one of the largest project holders. Management has identified 12 targets for drilling and if successful, further targets will certainly follow. The company is still at the beginning of its value development with a market value of CAD 15 million.

    A major producer is emerging

    SolGold is a major exploration company focused on the discovery and definition of copper-gold deposits. The company has established a reputation in Ecuador and has been able to secure a little-explored section of the Andean Copper Belt. Several copper and gold projects have been discovered and it is believed that half of the world's copper resources are located there. Between 2010 and 2019 SolGold discovered 10% of all gold discoveries worldwide.

    SolGold has defined 21.7 million ounces of gold, 9.9 million tonnes of copper and 92.2 million ounces of silver at the Alpala project in Ecuador to date. The Company now intends to complete a pre-feasibility study for its Cascabel project. By February 2020, SolGold had completed over 227,000 meters of drilling at Cascabel. For the future, annual production of 150,000 tons of copper and 245,000 ounces of gold is projected. Demand for copper will continue to grow in connection with the electrification of society and the gold price has known only one direction for months - soon it seems that the USD 2,000.00 per ounce mark will be reached. SolGold is valued at CAD 827 million on the stock exchange and has corresponding price potential, as the company's market capitalization is far below the value of Alpala alone, without taking into account the value of the 13 other projects.

    Only green energy for hydrogen makes sense

    NEL ASA is a plant engineering company from Norway that focuses on the production and sale of hydrogen. The company supplies key components for the development of an infrastructure for hydrogen-based electromobility. In Germany, there are currently about 14,000 filling stations set up for the sale of gasoline and diesel. If the development of vehicles with fuel cells for the generation of electricity from hydrogen continues to advance and meets with interest from buyers, then NEL ASA's market potential is correspondingly large.

    Against the background that sufficient renewable energy must be available for the production of green hydrogen, a clean environmental balance can currently only be achieved in a few regions on earth. As long as coal has to be burned to generate electricity for the production of hydrogen, modern diesel engines have a better standing in society. The market value of NEL ASA is currently around EUR 2.5 billion.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read